Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASN51 PET and PD study in healthy subjects
NCT05725005Phase 1Completed
- Sponsor
- Asceneuron SA
- Start
- Jan 2023
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ASN51 in Alzheimer's disease (AD), Parkinson's disease (PD) and amyotrophic lateral sclerosis (ALS) (2 arms), sponsored by Asceneuron SA. Primary endpoints: Mean Protein O-GlcNAcylation in Peripheral Blood Mononuclear Cells (PBMCs) and Regional Total Volume of Distribution (VT) of [18F]-IMA601 at Day 10. Started Jan 2023; status: completed.
02
Drugs
ASN51
03
Conditions
Alzheimer's disease (AD)Parkinson's disease (PD)amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT05725005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05725005.